Clinical and laboratory signs and risk factors for nephrotoxicity, associated with antiangiogenic drugs
Background. Anti-angiogenic anticancer drugs that block the vascular endothelial growth factor signaling pathway can cause renal damage. Assessment of the risk of nephrotoxicity allows developing optimal treatment approaches and ensuring the relative safety of therapy. Aim. To assess early clinic...
Main Authors: | Katerina S. Grechukhina, Natalia V. Chebotareva, Liudmila G. Zhukova, Tatiana N. Krasnova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
"Consilium Medicum" Publishing house
2021-06-01
|
Series: | Терапевтический архив |
Subjects: | |
Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/75941/56489 |
Similar Items
-
Nephrotoxicity of anti-angiogenesis drugs
by: Katerina S. Grechukhina, et al.
Published: (2020-07-01) -
Photodynamic therapy – hypericin tetraether liposome conjugates and their antitumor and antiangiogenic activity
by: Nikola Plenagl, et al.
Published: (2019-01-01) -
Mitomycin C-Induced Renal Insufficiency: A Case Report
by: Mei-Chin Wen, et al.
Published: (2003-06-01) -
Nephrotoxic characteristics of anti-tuberculosis drugs
by: G. N. Mozhokina, et al.
Published: (2019-11-01) -
Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review
by: Ling Gao, et al.
Published: (2019-10-01)